Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fuel efficiency of Wärtsilä 31 engine a key consideration for newbuild Canadian Polar Icebreaker

Wärtsilä Corporation, Trade press release, 30 April 2024 at 11:00 AM EESTTechnology group Wärtsilä will supply the engines for a new Canadian Coast Guard Polar Icebreaker. The ship is being designed and built at Seaspan Vancouver Shipyards and will be the flagship of the Canadian Coast Guard’s icebreaking fleet. Because of the long operational range required for the vessel’s employment in arctic waters, fuel efficiency was a prime design consideration in the selection of the Wärtsilä 31 engine.  The Wärtsilä 31 engine has been recognised by Guinness World Records

Number of shares and votes in Medicover

The number of shares and votes in Medicover AB (publ) (“Medicover ” or the “company”) has changed as a result of conversions of in total 33,300 class A shares into B shares carried out in April following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,631,101 are class A shares, together carrying 76,631,101 votes, 73,021,272 are class B shares, together carrying 7,302,127.2 votes and 3,882,822 are

Genexis Sustainability Report 2023: EcoVadis Gold and approved Science-based Targets

In 2023 Genexis made significant progress in sustainability, reinforcing the company's commitments to proactively minimize our carbon footprint, develop the well-being of our people, and engage and promote a responsible supply chain.“We are proud of our sustainability efforts, and we aspire to be a frontrunner in our industry by setting an example of our genuine commitment and long-term ambition,” says Olivier van Duuren, Sustainability officer at Genexis.  2023 sustainability highlights: Achieved EcoVadis gold medal: from a globally recognized authority on sustainability assessments,

Altor-backed Network of Design partners up with the Finnish disruptor Vaarnii

Network of Design (NOD) launched in 2020 to bring carefully selected Nordic design to every corner of the world. Today, NOD is proud to announce our investment in Vaarnii, a furniture company that makes brutally sophisticated objects from a single raw material, Finnish pine. All made by local craftspeople and workshops in Finland.Vaarnii was founded in 2021 by Antti Hirvonen and Miklu Silvanto with a vision to create simple pieces that will last for generations and kickstart a new era of sustainable furniture. Each Vaarnii collection begins with raw pine, chosen for its Finnishness and

#24-37 Rights issue in Implementa Sol AB

With the support of the authorization from the annual general meeting on April 26, 2024, the board of Implementa Sol AB (“the Company”) has decided on a rights issue with preferential rights for the Company’s existing shareholders.   The last day of trading in the Company’s shares including the right to receive subscription rights is April 30, 2024. The first day of trading in the Company’s shares excluding the right to receive subscription rights is May 2, 2024. The record date is May 3, 2024.   The shareholders of the Company will receive one (1) subscription right for each

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 99 – 30 APRIL 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 96/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Enersense signs an agreement to maintain the Valoo fibre-optic network in Southern Finland

Enersense International PlcInvestor news, 30 April 2024 at 10.45 a.m.Enersense, a provider of zero-emission energy solutions, and Valoo Oy, a Finnish fibre-optic network company, have signed an agreement on the maintenance of Valoo’s fibre-optic network. The two-year agreement includes the maintenance and further construction of the Valoo fibre-optic network in Southern Finland and will be recorded in Enersense Connectivity’s order books for the second quarter of 2024. The agreement can be extended by exercising a two-year option. “During the last 12 months, the Valoo fibre-optic

Win a Golden Ticket to Gotland - Sweden´s Summer Island!

Gotland, all-inclusive - for you and three others in July 2024 completely free! Too good to be true? It's true; enjoy Gotland´s legendary hospitality with accommodation, fantastic food, experiences to remember and ferry travel from the mainland for the winner. Gotland has several beautiful beaches for you to enjoy. Credits: Henrik Trygg/imagebank.sweden.se Region Gotland, together with the tourism industry in Gotland, has created this competition to highlight the beautiful island as a place to both visit and live, and to showcase the great range of sustainable experiences

Invitation to presentation of Storskogen’s interim report for the first quarter 2024

On 7 May 2024 at 07:00 (CEST), Storskogen announces its interim report for the first quarter 2024. In connection with the announcement, Christer Hansson, Interim CEO, and Lena Glader, CFO, will hold a presentation followed by a Q&A session. The presentation will be in English and starts at 09:00 (CEST).The presentation and the subsequent Q&A can be followed via webcast or telephone conference. For participation via webcast, please use the following link:https://ir.financialhearings.com/storskogen-group-q1-report-2024   If you wish to participate via telephone conference, please

Notice of annual general meeting in Chosa Oncology AB

The shareholders of Chosa Oncology AB, Reg. No. 559037-2271, are invited to attend the annual general meeting to be held on Friday 31 May 2024 at 1.00 p.m. at Medicon Village, in the main building the Spark, conference room Collaboraction, Scheeletorget 1, Lund, Sweden.Right to participate and notification Shareholders wishing to participate in the annual general meeting must: · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Thursday 23 May 2024; and · partly have notified their participation no later than on Monday 27 May 2024 by post to Chosa

BioStock: Annexin's phase II study fully recruited with positive signals

Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.Read the article about Annexin Pharmaceuticals here: https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/ 

Risk Intelligence enters partnership with Bosch Logistic Operating System for LandRisk Logistics

Risk Intelligence A/S (“Risk Intelligence” or the “Company") announces today that the company has signed a partnership agreement with Bosch Logistics Operating System (“Bosch L.OS”) for integration of Bosch Secure Truck Parking with the LandRisk Logistics as well as referral of Bosch L.OS clients to Risk Intelligence.Through the partnership with Bosch L.OS, users of LandRisk Logistics will be able to seamlessly book and pay for Bosch Secure Truck Parking spaces via the Risk Intelligence System. The integration via Bosch L.OS provides an end-to-end solution for manufacturers and logistics

Publication of Anora’s Interim Report for January–March 2024 on 7 May 2024 and invitation to results presentation

Anora Group Plc   Press release   30 April 2024 at 10:00 a.m. EEST Publication of Anora’s Interim Report for January–March 2024 on 7 May 2024 and invitation to results presentation Anora will publish its Interim Report for January–March 2024 on Tuesday 7 May 2024 at around 8:30 am EEST. CEO Jacek Pastuszka and CFO Sigmund Toth will present the report on the same day at 11:00 am EEST. The presentation will be held as a Microsoft Teams Meeting and we recommend joining the event through the online option: Join meeting here 

AEGIRBIO AB ADVANCES FURTHER WITH “ACCESSIBILITY” MILESTONE COMPLETION IN RADx® TECH PROGRAM

Pioneering Accessibility Project for Multiplex Testing Reaches Key Development MilestoneAegirBio AB is thrilled to announce the successful completion of a pivotal milestone within the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. Building on the award, AegirBio continues to drive innovation with its digital multiplex self-test platform, specifically designed to improve accessibility for individuals with visual, hearing, and dexterity impairments. The RADx® Tech program, dedicated to expediting diagnostic technology, granted AegirBio an award

New number of shares and votes in Storskogen

The number of shares and votes in Storskogen Group AB (publ) (“Storskogen”), as of today, amounts to 1,686,091,991 (of which 148,001,374 A-shares and 1,538,090,617 B-shares) and 3,018,104,357 votes.As previously announced, the number of shares and votes in Storskogen changed in April due to the conversion of the convertibles which were issued to the sellers of AC Electrical Services Limited on 3 April 2023 totalling GBP 10,361,992 to, in total, 16,561,182 B-shares. The conversion was registered with the Swedish Companies Registration Office on 3 April 2024. The number of shares and votes

The Swiftie Influence: The Top 5 Most Popular Pet Names Inspired By Taylor Swift

Where there are pet owners… there are also Swifties! As a self-proclaimed cat-lover, Taylor Swift has taken the world by storm with her infamous Eras Tour, as well as being recently crowned Spotify’s most listened-to artist of 2023.[1][red iphone 5 c on black textile]     And now, the countdown for her UK tour leg is in motion – with less than six weeks to go until Taylor graces the UK with her presence. As such, it’s of no surprise that many pet owners are consciously (or perhaps even subconsciously) inspired by her when naming their furry friends.   With a notable spike in

CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators

Lund, Sweden, April 30, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today congratulates its partner ClearPoint Neuro on receiving 510(k) clearance for its Prism Bone Anchor Accessory, expanding the use of ClearPoint Prism Neuro Laser Therapy System beyond the MRI into the operating room.The introduction of the Prism Bone Anchor Accessory for use with the ClearPoint Prism Neuro Laser Therapy System and commercially available stereotactic systems allows for placement of laser applicators also in the operating room.   “The 510(k) clearance of the Prism Bone

Archer Limited: Archer secures a 2-year contract extension worth USD 40 million

Hamilton Bermuda, (April 30, 2024) Archer has been awarded a two-year contract extension for platform drilling services in the UK with an estimated contract value of USD 40 million. The extension will commence 1[st] May 2024 in direct continuation of the current contract. Over the next two years Archer will continue to deliver drilling operations, maintenance and rig reactivation services for the customer. Alexander Olsson, EVP Platform Operations in Archer comments: ‘’We are delighted that Archer was elected to continue the work for our client. This contract extension reflects our

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months”   January – MarchFinancial summary for the quarter · Net turnover amounted to SEK 0.5 (0.4) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.7 (-18.9) million. Basic and diluted earnings per share amounted to SEK -0.23 (-0.34) and SEK -0.23 (-0.34) respectively. · Cash flow from operating

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q1 2024

For the second year in a row, we show a positive operating profit for the first quarter. This despite weak construction and consumer markets that resulted in a negative sales development of -12% to MSEK 38.2 (43.5). Thanks to a positive change in product mix and good sales of our own consumer brands, the Group’s gross margin strengthened to 29 (26) %. This, in combination with sound cost control, resulted in a slightly improved operating profit of MSEK 0.2 (0.1).Translation from CEO Mårten Hellbergs comments to the Interim Report. Q1, 1 January - 31 March 2024 The Group compared with

Safello enters into framework agreement with the Swedish Economic Crime Authority

Stockholm, April 30, 2024 | Safello, the leading cryptocurrency exchange in the Nordics, has entered into a framework agreement with the Swedish Economic Crime Authority. The framework agreement between the parties was concluded following a public procurement process conducted by the Swedish Police Authority to meet the needs of the Police Authority, the Swedish Customs Service, and the Economic Crime Authority for cryptocurrency services, which Safello won in August 2023. The procurement was carried out in accordance with the Swedish Public Procurement Act (Lagen om offentlig upphandling, “

Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control

· SHINE is the largest ongoing clinical study of its kind, marking a milestone in research on prediabetes and weight control. It involves individuals who are living with excess weight or obesity and have prediabetes or type 2 diabetes. · SiPore21® Silica "Molecular Sieves" is a promising, non-pharmaceutical oral alternative to injectable drugs for sustainable weight control.Stockholm, April 30th, 2024: Sigrid Therapeutics announced today that it has enrolled more than half of the necessary participants for its clinical trial SHINE of SiPore21®. SHINE is a randomized, double-blind,

There are no items matching the current filter
There are no more items matching the current filter
Back to top